GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Cash, Cash Equivalents, Marketable Securities

Helix BioPharma (TSX:HBP) Cash, Cash Equivalents, Marketable Securities : C$1.64 Mil (As of Oct. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Cash, Cash Equivalents, Marketable Securities?

Helix BioPharma's quarterly cash, cash equivalents, marketable securities declined from Apr. 2023 (C$1.33 Mil) to Jul. 2023 (C$0.81 Mil) but then increased from Jul. 2023 (C$0.81 Mil) to Oct. 2023 (C$1.64 Mil).

Helix BioPharma's annual cash, cash equivalents, marketable securities declined from Jul. 2021 (C$3.57 Mil) to Jul. 2022 (C$3.25 Mil) and declined from Jul. 2022 (C$3.25 Mil) to Jul. 2023 (C$0.81 Mil).


Helix BioPharma Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Helix BioPharma's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Cash, Cash Equivalents, Marketable Securities Chart

Helix BioPharma Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 4.24 3.57 3.25 0.81

Helix BioPharma Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 2.82 1.33 0.81 1.64

Helix BioPharma Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Helix BioPharma  (TSX:HBP) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Helix BioPharma Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma (TSX:HBP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
401 Bay Street, Suite 2704, Toronto, ON, CAN, M5H 2Y
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

Helix BioPharma (TSX:HBP) Headlines